Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors.

Yoichi NaitoSeigo NakamuraNobuko Kawaguchi-SakitaTakanori IshidaTakahiro NakayamaYutaka YamamotoNorikazu MasudaKoji MatsumotoTakahiro KogawaKazuki SudoAkihiko ShimomuraCatherine LaiDanjie ZhangYuki IwahoriDianna GaryDanh HuynhHiroji Iwata

Published in: International journal of clinical oncology (2024)

SG RP2D was established as 10 mg/kg in Japanese patients. SG showed efficacy in Japanese patients with previously treated mTNBC, a manageable safety profile, and no new safety signals, consistent with the previous ASCENT study.

Keyphrases

open label
clinical trial
randomized controlled trial
newly diagnosed
placebo controlled